Variables (units) [usual range]
Hemoglobin (g/dL) [4-20]A possible conversion for Hb values:
10 g/dL= 6.2 mmol/L, 8 g/dL= 5.0 mmol/L
Value
Absolute Neutrophil Count (x109/L) [0-15]
Platelets (x109/L) [0-2000]
Bone Marrow Blasts (percent) [0-30]
Cytogenetic Category
Very Good Good Intermediate Poor Very Poor IPSS-R SCORE
IPSS-R CATEGORY
Age-adjusted calculation of risk (IPSS-RA):
(only for survival estimation)
Age Years
(only for survival estimation)
Age Years
IPSS-R SCORE
IPSS-R CATEGORY(including age)
IPSS-R Cytogenetic risk groups*,**
| Cytogenetic prognostic subgroups | Cytogenetic abnormalities |
| Very good | -Y, del(11q) |
| Good | Normal, del(5q), del(12p), del(20q), double including del(5q) |
| Intermediate | del(7q), +8, +19, i(17q), any other single or double independent clones |
| Poor | -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities |
| Very poor | Complex: >3 abnormalities |
IPSS-R Prognostic Score Values*
| Prognostic variable | 0 | 0.5 | 1 | 1.5 | 2 | 3 | 4 |
| Cytogenetics | Very Good | Good | Intermediate | Poor | Very Poor | ||
| BM Blast % | <=2 | >2-<5% | 5-10% | >10% | |||
| Hemoglobin | =>10 | 8-<10 | <8 | ||||
| Platelets | =>100 | 50-<100 | <50 | ||||
| ANC | =>0.8 | <0.8 |
IPSS-R Prognostic Risk Categories/Scores*
| RISK CATEGORY | RISK SCORE |
| Very Low | <=1.5 |
| Low | >1.5 - 3 |
| Intermediate | >3 - 4.5 |
| High | >4.5 - 6 |
| Very High | >6 |
IPSS-R: Prognostic Risk Category Clinical Outcomes*
***Medians, years ^Median time to 25% AML evolution
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820
| No. pts | Very Low | Low | Intermediate | High | Very High | |
| Patients (%) | 7012 | 19% | 38% | 20% | 13% | 10% |
| Survival*** | 8.8 | 5.3 | 3.0 | 1.6 | 0.8 | |
| AML/25%***,^ | NR | 10.8 | 3.2 | 1.4 | 0.7 | |
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820
